Soluble receptor for advanced glycation end-products and progression of airway disease

BMC Pulmonary Medicine

Table 3 Correlations between plasma sRAGE concentrations and longitudinal changes in lung function

	All		Non-smokers		Smokers without COPD		Smokers with COPD
	(n = 295)		(n = 32)		(n = 212)		(n = 51)
	r	p-value	r	p-value	r	p-value	r	p-value
ΔFVC	-0.043	0.466	-0.142	0.438	-0.033	0.637	-0.031	0.828
ΔFVC % predicted	-0.047	0.432	-0.187	0.540	-0.033	0.632	-0.014	0.922
ΔFEV1	0.061	0.294	-0.115	0.529	0.008	0.907	0.240	0.090
ΔFEV1 % predicted	0.059	0.332	-0.215	0.481	0.029	0.680	0.269	0.056
ΔFEV1/FVC	0.149	0.010*	0.259	0.153	0.053	0.445	0.326	0.019*

*: p < 0.05; (correlation with plasma sRAGE levels, by Spearman’s rank correlation coefficient).
COPD, Chronic obstructive pulmonary disease; Δ: changes from baseline after 4 years; FEV ₁, Forced expiratory volume in 1 s; FVC, Forced vital capacity; sRAGE, Soluble receptor for advanced glycation end-products.

ISSN: 1471-2466